Latest news with #ParisHotel&Casino
Yahoo
21-04-2025
- Business
- Yahoo
Shuttle Pharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025
Company to conduct 1x1 meetings on April 24, 2025 GAITHERSBURG, Md., April 21, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ('Shuttle Pharma' or the 'Company'), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub on Wednesday, April 23, 2025, at 2:30 p.m. Pacific Time (5:30 p.m. Eastern Time). Anatoly Dritschilo, M.D., Chairman of the Board of Directors and Chief Scientific Officer of Shuttle Pharma, will be hosting the presentation and answering questions at the conclusion. Dr. Dritschilo's presentation will focus on providing an overview and update on the Company's ongoing Phase 2 trial of Ropidoxuridine and RT for treatment of patients with glioblastoma as well as advancements being made in the Company's Shuttle Diagnostics subsidiary which aims to develop pretreatment diagnostic blood tests and imaging agents for prostate cancer patients. To access the live presentation, please use the following information: Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub Date: Wednesday, April 23, 2025 Time: 2:30 p.m. Pacific Time (5:30 p.m. Eastern Time) Location: Track 3 – Chablis at the Paris Hotel & Casino in Las Vegas, NV Webcast: If you would like to schedule a 1x1 meeting with management, please contact your Planet MicroCap representative or the Company's investor relations team at 1x1@ 1x1 meetings will be scheduled and conducted in person at the conference venue: Paris Hotel & Casino in Las Vegas, NV About Shuttle Pharmaceuticals Founded in 2012 by faculty members of the Georgetown University Medical Center, Shuttle Pharma is a discovery and development stage specialty pharmaceutical company focused on improving the outcomes for cancer patients treated with radiation therapy (RT). Our mission is to improve the lives of cancer patients by developing therapies that are designed to maximize the effectiveness of RT while limiting the side effects of radiation in cancer treatment. Although RT is a proven modality for treating cancers, by developing radiation sensitizers, we aim to increase cancer cure rates, prolong patient survival and improve quality of life when used as a primary treatment or in combination with surgery, chemotherapy and immunotherapy. For more information, please visit our website at Safe Harbor Statement Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute 'forward-looking statements.' These statements include, but are not limited to, statements concerning the development of our company. The words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including factors discussed in the 'Risk Factors' section of Shuttle Pharma's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on February 26, 2025, as well other SEC filings. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, Shuttle Pharmaceuticals specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Shuttle PharmaceuticalsAnatoly Dritschilo, and Chief Scientific Officer240-403-4212info@ Investor ContactsLytham Partners, LLCRobert Blum602-889-9700shph@
Yahoo
21-04-2025
- Business
- Yahoo
Precision Optics to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025
Company to conduct 1x1 meetings on April 24, 2025 GARDNER, Mass., April 21, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub on Wednesday, April 23, 2025, at 4:00 p.m. Pacific Time (7:00 p.m. Eastern Time). Dr. Joe Forkey, Chief Executive Officer of Precision Optics, will be hosting the presentation and answering questions at the conclusion. To access the live presentation, please use the following information: Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub Date: Wednesday, April 23, 2025Time: 4:00 p.m. Pacific Time (7:00 p.m. Eastern Time)Location: Track 3 – Chablis at the Paris Hotel & Casino in Las Vegas, NVWebcast: If you would like to schedule a 1x1 meeting with management, please contact your Planet MicroCap representative or the Company's investor relations team at 1x1@ 1x1 meetings will be scheduled and conducted in person at the conference venue: Paris Hotel & Casino in Las Vegas, NV About Precision Optics CorporationFounded in 1982, Precision Optics is a vertically integrated optics company primarily focused on leveraging its proprietary micro-optics, 3D imaging and digital imaging technologies to the healthcare and defense/aerospace industries by providing services ranging from new product concept through mass manufacture. Utilizing its leading-edge in-house design, prototype, regulatory and fabrication capabilities as well as its Ross Optical division's high volume world-wide sourcing, inspecting and production resources, the Company is able to design and manufacture next-generation product solutions to the most challenging customer requirements. Within healthcare, Precision Optics enables next generation medical device companies around the world to meet the increasing demands of the surgical community who require more enhanced and smaller imaging systems for minimally invasive surgery as well as 3D endoscopy systems to support the rapid proliferation of surgical robotic systems. In addition to these next generation applications, Precision Optics has supplied top tier medical device companies a wide variety of optical products for decades, including complex endocouplers and specialized endoscopes. The Company is also leveraging its technical proficiency in micro-optics to enable leading edge defense/aerospace applications which require the highest quality standards and the optimization of size, weight and power. For more information, please visit About Forward-Looking Statements This press release contains forward-looking statements within the meaning of U.S. federal securities laws. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In addition, any statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "would" and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. The forward-looking statements contained in this press release are based on certain assumptions and analyses made by the management of the Company in light of their respective experience and perception of historical trends, current conditions, and expected future developments and their potential effects on the Company as well as other factors they believe are appropriate in the circumstances. There can be no assurance that future developments affecting the Company will be those anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the control of the parties), or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, including the demand for the Company's products, global supply chains and economic activity in general and other risks and uncertainties identified in the Company's filings with the SEC. Should one or more of these risks or uncertainties materialize or should any of the assumptions being made prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities laws. Company Contact: PRECISION OPTICS CORPORATION22 East BroadwayGardner, Massachusetts 01440-3338Telephone: 978-630-1800 Investor Contact:LYTHAM PARTNERS, LLCRobert BlumTelephone: 602-889-9700poci@ in to access your portfolio
Yahoo
16-04-2025
- Business
- Yahoo
electroCore to Participate at the Planet MicroCap Showcase
ROCKAWAY, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate in the Planet MicroCap Showcase taking place at the Paris Hotel & Casino in Las Vegas on April 23 & 24, 2025. Dan Goldberger, CEO, will host a group presentation on Wednesday, April 23, 2025 at 1:30 p.m. PT and host one-on-one meetings throughout both days. To schedule a one-on-one meeting with Mr. Goldberger, investors are encouraged to reach out to Planet MicroCap or electroCore's investor relations at ecor@ About electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health through its non-invasive vagus nerve stimulation ('nVNS') technology platform. Our focus is the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets. For more information, visit Contact ECOR Investor Relations(973) 302-9253investors@ in to access your portfolio
Yahoo
11-04-2025
- Business
- Yahoo
Rubicon Organics to Present at The Planet MicroCap Showcase in Las Vegas, NV and at ICBC Berlin B2B in Berlin, Germany
VANCOUVER, British Columbia, April 11, 2025 (GLOBE NEWSWIRE) -- Rubicon Organics Inc. (TSXV: ROMJ) (OTCQX: ROMJF) ('Rubicon Organics' or the 'Company'), is Canada's leading premium licensed producer focused on cultivating and selling organic certified and premium cannabis products and ultra-premium products, is pleased to announce its upcoming participation in two industry events: the Planet MicroCap Showcase: VEGAS 2025, taking place April 22–24, 2025, at the Paris Hotel & Casino in Las Vegas, Nevada, and the International Cannabis Business Conference ('ICBC') Berlin B2B scheduled for April 29–30, 2025, at the Estrel Berlin Hotel in Berlin, Germany. Planet MicroCap Showcase: VEGAS 2025 Rubicon Organics will deliver a company presentation on Wednesday, April 23, 2025, followed by one-on-one investor meetings with Margaret Brodie, Chief Executive Officer ('CEO'), on Thursday, April 24, 2025. A webcast of the presentation will be available live and for replay via the link below. Presentation Details: Date: April 23ʳᵈ, 2025Time: 11:30 AM PSTLocation: Paris Hotel & Casino, Las Vegas, NV, USAWebcast: Link If you would like to book 1x1 investor meetings with Rubicon Organics and to attend the Planet MicroCap Showcase: VEGAS 2025, please make sure you are registered here. ICBC Berlin B2B Margaret Brodie, CEO, will join a panel discussion on Tuesday, April 29, 2025, as part of the ICBC Berlin B2B event. The panel will feature industry executives, policymakers, and international experts discussing key issues shaping the future of the cannabis B2B ecosystem. Panel Discussion Details: Date: April 29ᵗʰ, 2025Panel Discussion Start Time: 11:45 AM CETLocation: Estrel Berlin Hotel, Berlin, Germany To register for the event, visit here. ABOUT RUBICON ORGANICS INC. Rubicon Organics Inc. is the global brand leader in premium organic cannabis products. The Company is vertically integrated through its wholly owned subsidiary Rubicon Holdings Corp, a licensed producer. Rubicon Organics is focused on achieving industry leading profitability through its premium cannabis flower, product innovation and brand portfolio management, including three flagship brands: its super-premium brand Simply Bare™ Organic, its premium brand 1964 Supply Co™, and its cannabis wellness brand Wildflower™ in addition to the Company's mainstream brand Homestead Cannabis Supply™. The Company ensures the quality of its supply chain by cultivating, processing, branding and selling organic certified, sustainably produced, super-premium cannabis products from its state-of-the-art glass roofed facility located in Delta, BC, Canada. CONTACT INFORMATION Margaret BrodieCEOPhone: +1 (437) 929-1964Email: ir@ The TSX Venture Exchange or its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) does not accept responsibility for the adequacy or accuracy of this press release. Cautionary Statement Regarding Forward Looking Information This press release contains forward-looking information within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, statements regarding Rubicon Organics' goal of achieving industry leading profitability are 'forward-looking statements'. Forward-looking information can be identified by the use of words such as 'will' or variations of such word or statements that certain actions, events or results 'will' be taken, occur or be achieved. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward looking statements. The forward-looking information in this press release is based on certain assumptions that management considers reasonable under the circumstances, including the Company's participation in the Planet MicroCap Showcase: VEGAS 2025 and ICBC Berlin B2B, the potential benefits of such event, the Company's financial performance, strategic expansion plans, market position, and future industry developments. These statements are based on current expectations, estimates, and projections about the Company's business and the industry in which it operates. Risks and uncertainties associated with the forward-looking information in this press release include, among others, risks related to regulatory approvals, changes in market conditions, competition, supply chain disruptions, the Company's ability to maintain certification standards, and the successful implementation of its business strategy. These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements. Although Rubicon Organics has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. Rubicon Organics assumes no obligation to update any forward-looking statement, even if new information becomes available as a result of future events, new information or for any other reason except as required by in to access your portfolio
